BioSante Pharmaceuticals, Inc. (BPAX)

[Just the facts maam]

BPAX hitting way above its weight in Science Strength

BIOTECHNOLOGY FROM TOP TO BOTTOM, BY SCIENCE STRENGTH

Monday, February 06, 2012

Below, companies and private research firms are grouped by their Patent Board science strength ranking which is based on the scale, quality, impact, and nearness to core science of a company's patent-based intellectual property. This overall strength rating factors in both qualitative and quantitative aspects of a company's patent portfolio. The charts help to spot the leaders in each group and across the board. All indicators based on 13-week rolling averages.

Patent Scorecard

Here are the top 16 companies that BPAX competes with and their market cap .

Roche Holding Ltd. (ADR) $162.94 billion
Johnson & Johnson $176.41 billion
Amgen, Inc. $53.62 billion
Biogen Idec Inc. $28.20 billion
Life Technologies Corp. $ 8.83 billion
Human Genome Sciences $ 1.89 billion
Merck & Co., Inc. $115.55 billion
ISIS Pharmaceuticals, Inc. $830.75 million
Bristol Myers Squibb Co. $54.06 billion
Alnylam Pharmaceuticals, Inc. $518.80 million
Sanofi SA (ADR) $99.94 billion
Immunomedics, Inc. $277.93 million
Incyte Corp $2.14 billion
Geron Corporation $262.29 million
Gilead Sciences, Inc. $40.48 billion
Amylin Pharmaceuticals, Inc. $ 2.51 billion
Biosante $93.62 million

You will notice that BPAX, Geron, Immunomedics, Alnylam and ISIS are the only companies with a market cap of less then $1.89 billion

Very Important:If you looked at the link I provided you will see that BPAX is the benchmark for research intensity.

This proves the science behind BPAX is solid.